A recent issue of Diabetes Care included a population-based case-control study by Bezin et al. (1) that has set off an alarm for diabetologists around the world. Bezin et al. attempted to address the issue of whether glucagon-like peptide 1 receptor agonists (GLP-1 RAs) were associated with thyroid cancer (TC) by using data from the French nationwide health care insurance system database. They looked at risk for TC according to GLP-1 RA use and cumulative duration of use. They showed that use of GLP-1 RAs for 1–3 years was associated with increased risk of all TC (adjusted hazard ratio 1.58, 95% CI 1.27–1.95) and medullary TC (adjusted hazard ratio 1.78, 95% CI 1.04–3.05). The authors concluded that clinicians should carefully monitor patients on GLP-1 RAs for the present risk.
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar